WELCOME

09.25 a.m. – 9.50 a.m.:

Liquid biopsy for solid tumors: from pre-analytic aspects to data interpretation.
Marzia Del Re, University of Pisa, Italy

09.50 a.m. – 10.20 a.m.:

Advancing Personalized Treatment in Metastatic Prostate Cancer: The ProBio Trial's Journey from Clinical Validity to Utility Using Cell-free DNA Biomarkers.
Bram De Laere, Dept. Human Structure and Repair, Ghent University

10.20 a.m. – 10.50 a.m.:

A Fast, Affordable, and Minimally Invasive Diagnostic Test for Cancer of Unknown Primary Using DNA Methylation Profiling.
Jilke De Wilde, Dept. Biomolecular Medicine, Ghent University

11.10 a.m. – 11.45 a.m.:

Clinical utility of cfDNA analysis in oncology.
Ed Schuuring, University of Groningen, The Netherlands

11.45 a.m.– 12.10 p.m.:

Deep-sequencing comprehensive liquid biopsy testing in real-world clinical practice: hopes and hypes.
Geert Martens, AZ Delta, Roeselare

12.10 p.m. – 12.35 p.m.:

Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology.
Kate Stanley, Dept. Human Genetics, University of Leuven

01.30 p.m. – 01.55 p.m.:

Exploring Liquid Biopsy Applications Across Tumor Indications: Clinical Insights from a Belgian Center
Henry Paridaens, Hôpital de la Citadelle, Liège

01.55 p.m. – 02.20 p.m.:

ctDNA in head and neck cancer: the path towards clinical utility.
Cédric van Marcke de Lummen, Medical Oncology, Saint-Luc UCLouvain, Brussels

02.20 p.m. – 02.45 p.m.:

Liquid biopsy plays a growing role in early-stage lung cancer.
Christophe Dooms, Dept. Pneumology, University Hospital Leuven

03.10 p.m. – 03.35 p.m.:

Leveraging Cell-Free Tumor DNA in Melanoma Research and Patient Care.
Iris Dirven, Dept. Medical Oncology, UZ Brussel